Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-2370

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-2370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm7 (Oxcarbazepine 300mg 70518 2370 01)

Label for OXcarbazepine 300 mg tablet, film coated, quantity 1, repackaged by RemedyRepack Inc. The label includes the product name, strength, dosage form, quantity, and manufacturer information (Breckenridge, Boca Raton, FL). It shows the NDC number 70518-2370-01 and advises storage conditions and to see package insert for directions.*

FDA Label Image

Remedy_label (Remedy Label)

Label for OXcarbazepine 300 mg film-coated tablets, quantity 100, repackaged by RemedyRepack Inc. The label includes the NDC 70518-2370-00, manufacturer Breckenridge in Boca Raton, FL, storage instructions, and a notice to keep medication out of children's reach.*

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine showing a dibenzazepine core with a ketone group and an amide substituent.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier survival curve showing exit rates over time from Day 2 to Day 11 in a clinical trial. The chart compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The y-axis represents exit rate from 0.0 to 1.0, and the x-axis shows time on trial in days. The log-rank test p-value is 0.0001, indicating a statistically significant difference between the groups.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve chart showing seizure rate over days from first dose to first seizure for two treatment groups: Oxcarbazepine and Placebo. The x-axis represents days up to 140, and the y-axis shows the seizure rate from 0.0 to 1.0. The chart includes a log-rank test p-value of 0.046 comparing the two groups' seizure rates over time.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier exit rate plot showing time to exit (days) on the horizontal axis and exit rate on the vertical axis. The chart compares two treatment groups labeled 'HIGH' and 'LOW' with a solid line and dotted line respectively. A log-rank test p-value of 0.0001 is noted, indicating statistical comparison between groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier survival curve chart depicting the exit rate over time in days. Two treatment groups are shown: HIGH (solid line) and LOW (dotted line). The y-axis represents exit rate from 0.0 to 1.0, and the x-axis represents time to exit in days from 0 to 130. A log-rank test with a p-value of 0.0001 is indicated on the chart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.